On August 18, 2017, the Patent Trial and Appeal Board (PTAB) ruled in favor of Finnegan client AstraZeneca, finding that Mylan Pharmaceuticals and other drug companies failed to show parts of AstraZeneca's patent covering its diabetes drugs Onglyza and Kombiglyze were invalid. The PTAB said it wasn't convinced someone experienced in pharmaceutical chemistry would have reasonably expected to have success making modifications to known compounds to arrive at those claimed in AstraZeneca’s patent. It also said there were additional considerations, including the failure of other compounds to obtain approval from the U.S. Food and Drug Administration for the treatment of diabetes, weighed against finding the patent claims obvious.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.